Abstract
Amaç: Kronik bir akciğer hastalığı olan pnömokonyozda sık sık influenza ve pnömoniye yakalanmak hastalığın seyrini kötüleştirir. Bu sebepten hastaların influenza ve pnömokok aşılarını olması önem arz eder. Çalışmanın amacı pnömokonyozlu hastaların influenza ve pnömoni hakkında bilgi düzeylerini ölçmek ve aşılı olma durumlarını belirlemektir.
Yöntem: Yetmiş üç pnömokonyoz tanılı hastaya ulaşarak mevsimsel grip ve pnömoni hakkında bilgileri ve aşılı olma durumlarını değerlendiren 26 soruluk anket bilgi formu doldurmalarını sağladık. Çalışma tanımlayıcı, kesitsel olarak tasarlandı. Hastaların sosyodemografik, sosyoekonomik özelliklerini, çalışma şartlarını da inceledik.
Bulgular: Biri kadın 73 hastanın yaş ortalaması 46,4±7,8 yıl idi. Hastalar çalışmaya orta ergenlik döneminden itibaren başlamış. Çoğu ilkokul mezunu ve gelir durumlarının yeterli olmadığını düşünüyorlardı. Hastaların üçte biri genel olarak aşı konusunda tereddütte idi. Grip ve zatürre aşısını duymayanlar vardı. Otuz dört hasta (%46,6) aşıları bizzat sağlıkçılardan değil, TV veya internetten duyduğunu söyledi. Pnömokonyoz teşhisi sonrası grip ve zatürre aşısı olma oranları çok düşüktü (sırasıyla, 14 hasta/%19,2 ve 16 hasta/%21,9). Hastaların üçte biri zatürrenin akciğer hastalığı olduğu, 41 hasta (%56,2) ise pnömokonyozun zatürre riskini artırdığı bilgisine sahip değildi. ‘‘Neden zatürre aşısı olmadınız?’’ diye sorduğumuzda ise ‘‘Bu bilgiye henüz yeni ulaştım’’ cevabı ön plana çıktı (39 hasta/%53,5). Pnömokonyoz teşhisi aldıktan sonra zatürre aşısı olmayan hastaların büyük çoğunluğu (42/57 hasta) zatürrenin aşıyla önlenebileceği bilgisine sahip değildi. Diğer taraftan aşıyı olanların çoğu önceden bu bilgiye sahip olduklarını söyledi (15/16 hasta) (p<0.001).
Sonuç: Pnömokonyozlu hastaların influenza ve pnömokok aşıları hakkında düzenli bilgi ve tavsiyeye ihtiyacı vardır.
Keywords
References
- 1. DeLight N, Sachs H. Pneumoconiosis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. PMID: 32310362
- 2. Qi XM, Luo Y, Song MY, Liu Y, Shu T, Liu Y, et al. Pneumoconiosis: current status and future prospects. Chin Med J (Engl). 2021;134(8):898-907. doi: 10.1097/CM9.0000000000001461.
- 3. Fan Y, Xu W, Wang Y, Wang Y, Yu S, Ye Q. Association of occupational dust exposure with combined chronic obstructive pulmonary disease and pneumoconiosis: a cross-sectional study in China. BMJ Open. 2020;10(9):e038874. doi: 10.1136/bmjopen-2020-038874.
- 4. T.C. Sağlık Bakanlığı Sağlık Hizmetleri Genel Müdürlüğü. Pnömokonyozlarda Sağlık Gözetimi, Klinik Tanı, Kayıt, Bildirim ve İzlem Protokolü. Ankara 2021. s.146 [T.R. Ministry of Health, General Directorate of Health Services. Health Surveillance, Clinical Diagnosis, Registration, Notification and Follow-up Protocol in Pneumoconiosis. Ankara 2021. p.146]. https://sbu.saglik.gov.tr/Ekutuphane/kitaplar/pnomkonyozklinikprotokol04032021pdf.pdf
- 5. Gaitonde DY, Moore FC, Morgan MK. Influenza: Diagnosis and Treatment. Am Fam Physician. 2019;100(12): 751-58. PMID: 31845781.
- 6. Pizzolla A, Wakim LM. Memory T Cell Dynamics in the Lung during Influenza Virus Infection. J Immunol. 2019;202 (2):374-81. doi: 10.4049/jimmunol.1800979.
- 7. Obert J, Burgel P-R. Pneumococcal infections: Association with asthma and COPD. Med Mal Infect. 2012;42(5):188-92. doi: 10.1016/j.medmal.2012.02.003.
- 8. Karadeniz G, Kılınç O, Ölmez A, Özhan MH, Özlü T, Özyürek BA, et al. Pneumococcal infections and protection with vaccination in adult chronic lung diseases. Tuberk Toraks 2020;68(3):305-20. doi: 10.5578/tt.70012.
- 9. Vemula SV, Sayedahmed EE, Sambhara S, Mittal SK. Vaccine approaches conferring cross-protection against influenza viruses. Expert Rev Vaccines. 2017;16(11):1141-54. doi: 10.1080/14760584.2017.1379396.
- 10. Bosaeed M, and Kumar D. Seasonal influenza vaccine in immunocompromised persons. Hum Vaccin Immunother. 2018;14(6):1311–22. doi: 10.1080/21645515.2018.1445446.
- 11. Kim GL, Seon SH, and Rhee DK. Pneumonia and Streptococcus pneumoniae vaccine. Arch Pharm Res. 2017;40(8):885–93. doi: 10.1007/s12272-017-0933-y.
- 12. Masanori A. Imaging diagnosis of classical and new pneumoconiosis: predominant reticular HRCT pattern. Insights Imaging. 2021;12(1):33. doi: 10.1186/s13244-021-00966-y.
- 13. Altınsoy B, Öz İİ, Erboy F, Atalay F. Emphysema and Airflow Obstruction in Non-Smoking Coal Miners with Pneumoconiosis. Med Sci Monit. 2016;22:4887-93. doi: 10.12659/msm.901820.
- 14. Chioma OS, Drake WP. Role of Microbial Agents in Pulmonary Fibrosis. Yale J Biol Med. 2017;90(2):219-27. PMID: 28656009.
- 15. Huang WJ, Tang XX. Virus infection induced pulmonary fibrosis. J Transl Med. 2021;19(1):496. doi: 10.1186/s12967-021-03159-9.
- 16. Sözen M, Karatoprak AP, Demirhan Y, Nasırlıer GÇ, Selek A, Gezer E, et al. Awareness of influenza and pneumococcal vaccines in diabetic patients. J Diabetes Metab Disord. 2021;20(1):757-63. doi: 10.1007/s40200-021-00812-4.
- 17. Kalil AC, Thomas PG. Influenza virus-related critical illness: pathophysiology and epidemiology. Crit Care. 2019;23(1):258. doi: 10.1186/s13054-019-2539-x.
- 18. Froes F, Roche N, Blasi F. Pneumococcal vaccination and chronic respiratory diseases. Int J Chron Obstruct Pulmon Dis. 2017;12:3457-68. doi: 10.2147/COPD.S140378.
- 19. Schoefer Y, Schaberg T, Raspe H, Schaefer T. Determinants of influenza and pneumococcal vaccination in patients with chronic lung diseases. J Infect. 2007;55(4):347-52. doi: 10.1016/j.jinf.2007.06.002.
- 20. Fekete M, Pako J, Nemeth AN, Tarantini S, and Varga JT. Prevalence of influenza and pneumococcal vaccination in chronic obstructive pulmonary disease patients in association with the occurrence of acute exacerbations. J Thorac Dis. 2020;12(8):4233–42. doi: 10.21037/jtd-20-814.
- 21. Jo BS, Lee J, Cho Y, Byun J, Kim HR, Koo JW, et al. Risk factors associated with mortality from pneumonia among patients with pneumoconiosis. Ann Occup Environ Med. 2016;28:19. doi: 10.1186/s40557-016-0103-6.
Abstract
Aims: In pneumoconiosis, which is a chronic lung disease, frequent seasonal flu and pneumonia worsen the course of the disease. Therefore, it is important that patients have seasonal flu and pneumococcal vaccines. The study aims to measure the knowledge level of patients with pneumoconiosis about influenza and pneumonia and to determine their vaccination status.
Methods: We reached 73 patients with pneumoconiosis and had them fill out a 26-question questionnaire that evaluated their information about influenza and pneumonia and their vaccination status. The study was designed as descriptive, cross-sectional. We also examined the sociodemographic, socio-economic characteristics and working conditions of the patients.
Results: The mean age of 73 patients, one of whom was female, was 46.4±7.8 years. They started working life in middle adolescence. Most of them are primary school graduates and they estimated their income was not sufficient. One-third of the patients were hesitant about vaccination in general. Some had not heard of the seasonal flu and pneumonia vaccine. Thirty-four patients (46.6%) said that they heard about the vaccines from the TV or the internet, not from the healthcare professionals. After the diagnosis of pneumoconiosis, influenza and pneumonia vaccination rates were very low (14 patients/19.2% and 16 patients/21.9%, respectively). One-third of the patients were unaware that pneumonia was a lung disease. When we asked, "Why haven't you been vaccinated against pneumonia?" the answer "I just got this information" came to the fore (39 patients/53.5%). Most patients (42/57 patients) who were not vaccinated against pneumonia after being diagnosed with pneumoconiosis were not aware that pneumonia could be prevented by vaccination (p<0.001). However, most of those who have been vaccinated said that they had this knowledge before (15/16 patients).
Conclusion: Patients with pneumoconiosis need regular information and advice about influenza and pneumococcal vaccines.
References
- 1. DeLight N, Sachs H. Pneumoconiosis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. PMID: 32310362
- 2. Qi XM, Luo Y, Song MY, Liu Y, Shu T, Liu Y, et al. Pneumoconiosis: current status and future prospects. Chin Med J (Engl). 2021;134(8):898-907. doi: 10.1097/CM9.0000000000001461.
- 3. Fan Y, Xu W, Wang Y, Wang Y, Yu S, Ye Q. Association of occupational dust exposure with combined chronic obstructive pulmonary disease and pneumoconiosis: a cross-sectional study in China. BMJ Open. 2020;10(9):e038874. doi: 10.1136/bmjopen-2020-038874.
- 4. T.C. Sağlık Bakanlığı Sağlık Hizmetleri Genel Müdürlüğü. Pnömokonyozlarda Sağlık Gözetimi, Klinik Tanı, Kayıt, Bildirim ve İzlem Protokolü. Ankara 2021. s.146 [T.R. Ministry of Health, General Directorate of Health Services. Health Surveillance, Clinical Diagnosis, Registration, Notification and Follow-up Protocol in Pneumoconiosis. Ankara 2021. p.146]. https://sbu.saglik.gov.tr/Ekutuphane/kitaplar/pnomkonyozklinikprotokol04032021pdf.pdf
- 5. Gaitonde DY, Moore FC, Morgan MK. Influenza: Diagnosis and Treatment. Am Fam Physician. 2019;100(12): 751-58. PMID: 31845781.
- 6. Pizzolla A, Wakim LM. Memory T Cell Dynamics in the Lung during Influenza Virus Infection. J Immunol. 2019;202 (2):374-81. doi: 10.4049/jimmunol.1800979.
- 7. Obert J, Burgel P-R. Pneumococcal infections: Association with asthma and COPD. Med Mal Infect. 2012;42(5):188-92. doi: 10.1016/j.medmal.2012.02.003.
- 8. Karadeniz G, Kılınç O, Ölmez A, Özhan MH, Özlü T, Özyürek BA, et al. Pneumococcal infections and protection with vaccination in adult chronic lung diseases. Tuberk Toraks 2020;68(3):305-20. doi: 10.5578/tt.70012.
- 9. Vemula SV, Sayedahmed EE, Sambhara S, Mittal SK. Vaccine approaches conferring cross-protection against influenza viruses. Expert Rev Vaccines. 2017;16(11):1141-54. doi: 10.1080/14760584.2017.1379396.
- 10. Bosaeed M, and Kumar D. Seasonal influenza vaccine in immunocompromised persons. Hum Vaccin Immunother. 2018;14(6):1311–22. doi: 10.1080/21645515.2018.1445446.
- 11. Kim GL, Seon SH, and Rhee DK. Pneumonia and Streptococcus pneumoniae vaccine. Arch Pharm Res. 2017;40(8):885–93. doi: 10.1007/s12272-017-0933-y.
- 12. Masanori A. Imaging diagnosis of classical and new pneumoconiosis: predominant reticular HRCT pattern. Insights Imaging. 2021;12(1):33. doi: 10.1186/s13244-021-00966-y.
- 13. Altınsoy B, Öz İİ, Erboy F, Atalay F. Emphysema and Airflow Obstruction in Non-Smoking Coal Miners with Pneumoconiosis. Med Sci Monit. 2016;22:4887-93. doi: 10.12659/msm.901820.
- 14. Chioma OS, Drake WP. Role of Microbial Agents in Pulmonary Fibrosis. Yale J Biol Med. 2017;90(2):219-27. PMID: 28656009.
- 15. Huang WJ, Tang XX. Virus infection induced pulmonary fibrosis. J Transl Med. 2021;19(1):496. doi: 10.1186/s12967-021-03159-9.
- 16. Sözen M, Karatoprak AP, Demirhan Y, Nasırlıer GÇ, Selek A, Gezer E, et al. Awareness of influenza and pneumococcal vaccines in diabetic patients. J Diabetes Metab Disord. 2021;20(1):757-63. doi: 10.1007/s40200-021-00812-4.
- 17. Kalil AC, Thomas PG. Influenza virus-related critical illness: pathophysiology and epidemiology. Crit Care. 2019;23(1):258. doi: 10.1186/s13054-019-2539-x.
- 18. Froes F, Roche N, Blasi F. Pneumococcal vaccination and chronic respiratory diseases. Int J Chron Obstruct Pulmon Dis. 2017;12:3457-68. doi: 10.2147/COPD.S140378.
- 19. Schoefer Y, Schaberg T, Raspe H, Schaefer T. Determinants of influenza and pneumococcal vaccination in patients with chronic lung diseases. J Infect. 2007;55(4):347-52. doi: 10.1016/j.jinf.2007.06.002.
- 20. Fekete M, Pako J, Nemeth AN, Tarantini S, and Varga JT. Prevalence of influenza and pneumococcal vaccination in chronic obstructive pulmonary disease patients in association with the occurrence of acute exacerbations. J Thorac Dis. 2020;12(8):4233–42. doi: 10.21037/jtd-20-814.
- 21. Jo BS, Lee J, Cho Y, Byun J, Kim HR, Koo JW, et al. Risk factors associated with mortality from pneumonia among patients with pneumoconiosis. Ann Occup Environ Med. 2016;28:19. doi: 10.1186/s40557-016-0103-6.
Details
| Primary Language | English |
|---|---|
| Subjects | Internal Diseases |
| Journal Section | Research Article |
| Authors | |
| Publication Date | December 31, 2022 |
| Submission Date | August 23, 2022 |
| Acceptance Date | November 6, 2022 |
| Published in Issue | Year 2022 Volume: 6 Issue: 3 |
This Journal is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.